Infectious complications following transrectal ultrasound-guided prostate biopsy: New challenges in the era of multidrug-resistant escherichia coli

Deborah A. Williamson, Lucinda K. Barrett, Benjamin A. Rogers, Joshua T. Freeman, Paul Hadway, David L. Paterson

Research output: Contribution to journalArticleResearchpeer-review

102 Citations (Scopus)

Abstract

Transrectal ultrasound (TRUS)-guided prostate biopsy is currently considered the standard technique for obtaining tissue to make a histological diagnosis of prostatic carcinoma. Infectious complications following TRUS-guided prostate biopsy are well described, and are reportedly increasing in incidence. The role of antibiotic prophylaxis in reducing post-TRUS biopsy infections is now established, and many guidelines suggest that fluoroquinolone antimicrobials are the prophylactic agents of choice. Of note, however, recent reports suggest an emerging association between TRUS biopsy and subsequent infection with fluoroquinolone-resistant Escherichia coli. Against this background, we provide an overview of the epidemiology, prevention, and treatment of infectious complications following TRUS biopsy, in the wider context of increasing global antimicrobial resistance.

Original languageEnglish
Pages (from-to)267-274
Number of pages8
JournalClinical Infectious Diseases
Volume57
Issue number2
DOIs
Publication statusPublished - 15 Jul 2013
Externally publishedYes

Keywords

  • ESBL
  • Escherichia coli
  • fluoroquinolones
  • prostate biopsy

Cite this